QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:VRNA

Verona Pharma (VRNA) News Today

$21.10
+0.41 (+1.98%)
(As of 06/8/2023 ET)
Compare
Today's Range
$20.38
▼
$21.54
50-Day Range
$19.41
▼
$23.43
52-Week Range
$3.85
▼
$26.44
Volume
247,193 shs
Average Volume
561,042 shs
Market Capitalization
$1.67 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.33
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media
Get Verona Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.



VRNA Media Mentions By Week

VRNA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VRNA
News Sentiment
▼
0.40

0.50
▲
Average
Medical
News Sentiment

VRNA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VRNA Articles
This Week
▼
4

3
▲
VRNA Articles
Average Week

SourceHeadline
msn.com logoTruist Securities Maintains Verona Pharma Plc - ADR (VRNA) Buy Recommendation
msn.com - June 7 at 11:48 PM
MarketBeat logoTruist Financial Raises Verona Pharma (NASDAQ:VRNA) Price Target to $32.00
americanbankingnews.com - June 7 at 8:34 AM
markets.businessinsider.com logoVerona Pharma (VRNA) Gets a Buy from H.C. Wainwright
markets.businessinsider.com - June 2 at 8:35 AM
marketbeat.com logoCommonwealth Equity Services LLC Invests $326,000 in Verona Pharma plc (NASDAQ:VRNA)
marketbeat.com - May 31 at 4:38 AM
marketbeat.com logoEnvestnet Asset Management Inc. Grows Holdings in Verona Pharma plc (NASDAQ:VRNA)
marketbeat.com - May 29 at 4:00 AM
msn.com logoVerona Pharma: Poised For A Breakthrough In COPD Treatment Amidst Favorable Financial Position
msn.com - May 28 at 10:05 AM
MarketBeat logoVerona Pharma plc (NASDAQ:VRNA) Receives Average Rating of "Buy" from Brokerages
americanbankingnews.com - May 24 at 2:46 AM
MarketBeat logoVerona Pharma (NASDAQ:VRNA) Trading Down 3.6%
americanbankingnews.com - May 19 at 8:28 AM
marketbeat.com logoVerona Pharma plc (NASDAQ:VRNA) Given Average Rating of "Buy" by Brokerages
marketbeat.com - May 19 at 3:50 AM
seekingalpha.com logoVerona Pharma: Revolutionizing COPD With First Triple Mechanism Inhaled Drug
seekingalpha.com - May 18 at 6:51 PM
MarketBeat logoVerona Pharma plc (NASDAQ:VRNA) Director Sells $1,780,800.00 in Stock
americanbankingnews.com - May 18 at 4:38 AM
MarketBeat logoOrbimed Advisors Llc Sells 359,713 Shares of Verona Pharma plc (NASDAQ:VRNA) Stock
americanbankingnews.com - May 17 at 4:46 AM
benzinga.com logoMassive Insider Trade At Verona Pharma
benzinga.com - May 16 at 12:44 PM
MarketBeat logoWedbush Weighs in on Verona Pharma plc's Q2 2023 Earnings (NASDAQ:VRNA)
americanbankingnews.com - May 16 at 1:26 AM
marketbeat.com logoVerona Pharma plc (NASDAQ:VRNA) Forecasted to Post Q2 2023 Earnings of ($0.27) Per Share
marketbeat.com - May 15 at 1:11 AM
seekingalpha.com logoVerona Pharma plc (VRNA) Q1 2023 Earnings Call Transcript
seekingalpha.com - May 13 at 10:11 AM
marketbeat.com logoAnalysts Offer Predictions for Verona Pharma plc's FY2027 Earnings (NASDAQ:VRNA)
marketbeat.com - May 12 at 10:58 AM
marketbeat.com logoVerona Pharma plc (NASDAQ:VRNA) Short Interest Up 21.8% in April
marketbeat.com - May 12 at 8:21 AM
msn.com logoCanaccord Genuity Maintains Verona Pharma Plc - ADR (VRNA) Below Average Recommendation
msn.com - May 12 at 1:55 AM
msn.com logoHC Wainwright & Co. Reiterates Verona Pharma Plc - ADR (VRNA) Buy Recommendation
msn.com - May 11 at 8:55 PM
MarketBeat logoVerona Pharma (NASDAQ:VRNA) Shares Gap Up to $21.87
americanbankingnews.com - May 11 at 7:13 AM
finanznachrichten.de logoVerona Pharma plc: Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
finanznachrichten.de - May 9 at 8:54 AM
finance.yahoo.com logoVerona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
finance.yahoo.com - May 9 at 8:54 AM
MarketBeat logoInsider Selling: Verona Pharma plc (NASDAQ:VRNA) General Counsel Sells $207,370.08 in Stock
americanbankingnews.com - May 6 at 5:48 AM
MarketBeat logoVerona Pharma plc (NASDAQ:VRNA) Insider Sells $199,753.92 in Stock
americanbankingnews.com - May 6 at 5:48 AM
MarketBeat logoKathleen A. Rickard Sells 28,752 Shares of Verona Pharma plc (NASDAQ:VRNA) Stock
americanbankingnews.com - May 6 at 5:48 AM
MarketBeat logoVerona Pharma plc (NASDAQ:VRNA) CEO Sells $1,175,282.88 in Stock
americanbankingnews.com - May 6 at 4:50 AM
MarketBeat logoVerona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 455,528 Shares of Stock
americanbankingnews.com - May 4 at 7:10 AM
finance.yahoo.com logoVerona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023
finance.yahoo.com - May 2 at 2:08 AM
marketbeat.com logoVerona Pharma plc (NASDAQ:VRNA) Shares Bought by AlphaCentric Advisors LLC
marketbeat.com - May 1 at 12:13 PM
MarketBeat logoVerona Pharma plc (NASDAQ:VRNA) Receives $29.33 Average Price Target from Brokerages
americanbankingnews.com - April 27 at 1:22 AM
finance.yahoo.com logoVerona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update
finance.yahoo.com - April 25 at 2:38 AM
marketbeat.com logoDekaBank Deutsche Girozentrale Invests $504,000 in Verona Pharma plc (NASDAQ:VRNA)
marketbeat.com - April 24 at 5:08 AM
marketbeat.com logoVerona Pharma plc (NASDAQ:VRNA) Receives Consensus Recommendation of "Buy" from Analysts
marketbeat.com - April 24 at 4:17 AM
MarketBeat logoVerona Pharma (NASDAQ:VRNA) Trading Up 6.4%
americanbankingnews.com - April 21 at 7:37 AM
msn.com logoTelecom, Pharma Stocks Lead European Equities Lower in Thursday Trading
msn.com - April 20 at 12:14 PM
seekingalpha.com logoVerona Pharma: Ensifentrine Vs. Dupixent, Ensifentrine Is A Breath Of Fresh Air
seekingalpha.com - April 16 at 12:45 PM
finance.yahoo.com logoWhen Will Verona Pharma plc (NASDAQ:VRNA) Breakeven?
finance.yahoo.com - April 11 at 7:43 AM
msn.com logoHC Wainwright & Co. Reiterates Verona Pharma (VRNA) Buy Recommendation
msn.com - April 10 at 9:19 PM
finance.yahoo.com logoNuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
finance.yahoo.com - April 10 at 8:49 AM
MarketBeat logoAnalysts Set Verona Pharma plc (NASDAQ:VRNA) PT at $29.33
americanbankingnews.com - April 2 at 1:14 AM
marketbeat.com logoMoody Aldrich Partners LLC Lowers Position in Verona Pharma plc (NASDAQ:VRNA)
marketbeat.com - March 31 at 2:34 PM
finance.yahoo.com logoTop Healthcare Stocks for April 2023
finance.yahoo.com - March 30 at 6:05 PM
marketbeat.com logoVerona Pharma plc (NASDAQ:VRNA) Receives Average Recommendation of "Buy" from Analysts
marketbeat.com - March 30 at 4:35 AM
seekingalpha.com logoBuy Verona Pharma For Its Strong COPD Contender
seekingalpha.com - March 28 at 12:18 PM
seekingalpha.com logoVerona's Ensifentrine: A Promising Novel Treatment For COPD Patients
seekingalpha.com - March 27 at 10:16 AM
MarketBeat logoBTIG Research Boosts Verona Pharma (NASDAQ:VRNA) Price Target to $31.00
americanbankingnews.com - March 23 at 3:12 AM
finance.yahoo.com logoVerona Pharma PLC American Depositary Share (VRNA) Stock Moves -0.46%: What You Should Know
finance.yahoo.com - March 22 at 8:45 PM
marketbeat.com logoVerona Pharma plc to Post Q3 2023 Earnings of ($0.32) Per Share, HC Wainwright Forecasts (NASDAQ:VRNA)
marketbeat.com - March 15 at 7:47 AM
msn.com logo4 Analysts Have This to Say About Verona Pharma
msn.com - March 13 at 7:25 PM
Get Verona Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:VRNA) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -